Neo-ACT Trial
Vitala supports the Neo-ACT trial, a randomized clinical study evaluating physical exercise during neoadjuvant chemotherapy for breast cancer.
Neo-ACT Trial
A randomized clinical study evaluating structured physical exercise during neoadjuvant chemotherapy for breast cancer — advancing the evidence base for exercise oncology and supportive cancer care.
Can exercise enhance the effect of chemotherapy?
The Neo-ACT trial is a randomized clinical study investigating whether structured physical exercise during neoadjuvant chemotherapy can improve pathological complete response (pCR) — the absence of invasive tumor after chemotherapy — in breast cancer patients. If successful, this study could change how exercise is prescribed during cancer treatment worldwide.
Approximately 9,000 women are diagnosed with breast cancer each year in Sweden alone, and neoadjuvant chemotherapy is increasingly used as a standard treatment. This trial is one of the first to rigorously test whether adding a structured exercise protocol to standard care can improve treatment outcomes at the cellular level.
Patients across multiple countries use the Vitala platform for this study.
Vitala delivers the exact high-intensity interval training protocol used in the research.
Results could change how exercise is prescribed alongside chemotherapy globally.
Powering the protocol behind the research.
Vitala provides the specific HIIT exercise protocol being used for the Neo-ACT research study. Patients from 20+ hospitals all over the world are using the Vitala platform to follow the program, log activity, and complete functional assessments — enabling remote delivery, adherence tracking, and outcome measurement for this one-of-a-kind study.
Partner with Vitala on research.
Bring structured exercise and lifestyle interventions into your clinical trials and research programs.